Research
Mixed
SGLT-2 inhibitors reduce body weight and visceral adiposity in Asian patients with type 2 diabetes, making them a preferred therapeutic option for overweight or obese patients.
If you have Type 2 Diabetes and are overweight, ask your doctor about SGLT-2 inhibitors (like Jardiance, Farxiga, or Invokana). Unlike older diabetes meds that often cause weight gain, these drugs help you lose weight and reduce belly fat while managing your blood sugar.
GoodSupportsHIGH confidence
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity.
Why this rating
Supported by multiple randomized controlled trials, CV outcome trials, and pooled analyses.
Source
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Wayne Huey‐Herng Sheu et al. · Diabetes & Metabolism Journal · 2020
narrative_reviewCited 51×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →